7.62
前日終値:
$7.49
開ける:
$7.57
24時間の取引高:
133.19K
Relative Volume:
1.03
時価総額:
$2.55B
収益:
$417.75M
当期純損益:
$32.27M
株価収益率:
78.15
EPS:
0.0975
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-5.11%
1か月 パフォーマンス:
-19.62%
6か月 パフォーマンス:
-53.82%
1年 パフォーマンス:
-49.20%
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
TLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
TLX
Telix Pharmaceuticals Ltd Adr
|
7.62 | 2.51B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-18 | 開始されました | Citigroup | Buy |
| 2025-08-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-07-03 | 開始されました | H.C. Wainwright | Buy |
| 2025-06-05 | 開始されました | Wedbush | Outperform |
| 2024-11-15 | 開始されました | UBS | Buy |
Telix Pharmaceuticals Ltd Adr (TLX) 最新ニュース
TLX 7-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain - GlobeNewswire Inc.
FCX IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Freeport-McMoRan Inc. Investors to Secure Counsel Before Important January 12 Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2026 in Telix Pharmaceuticals Ltd. LawsuitTLX - Sahm
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages F5, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Class Action Filed Against Telix Pharmaceuticals Ltd. (TLX)January 9, 2026 Deadline to JoinContact Levi & Korsinsky - Sahm
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages F5, Inc. Stockholders to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
[6-K] Telix Pharmaceuticals Ltd Current Report (Foreign Issuer) | TLX SEC FilingForm 6-K - Stock Titan
Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Finviz
Telix Pharma (TLX) Makes Progress With New Study - Finviz
Telix Pharmaceuticals (TLX) files Form 6-K on first ProstACT Global patient - Stock Titan
ATTENTION NASDAQ: TLX INVESTORS: Contact Berger Montague About a Telix Pharmaceuticals Ltd. Class Action Lawsuit - Stock Titan
Telix Pharmaceuticals (TLX) Sued After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman - Finviz
Telix Pharmaceuticals (TLX) Hit with Investor Lawsuit Alleging Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman - Finviz
Investors in Telix Pharmaceuticals Ltd. Should Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your RightsTLX - Finviz
Berger Montague PC Investigating Claims on Behalf of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors After Class Action Filing - Stock Titan
TLXTelix Pharmaceuticals Ltd ADR Latest Stock News & Market Updates - Stock Titan
Berger Montague PC Investigating Claims on Behalf of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) After Class Action Filing - Stock Titan
Telix Pharmaceuticals Limited Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsTLX - Stock Titan
TELIX PHARMACEUTICALS INVESTIGATION ALERT: Bragar Eagel & - GlobeNewswire
Telix Pharmaceuticals Ltd Adr (TLX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):